Morphic Holding, Inc. (NASDAQ:MORF) CAO Robert E. Farrell, Jr. sold 3,049 shares of the business’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $65.01, for a total value of $198,215.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Morphic stock traded up $1.38 on Tuesday, reaching $66.86. The company’s stock had a trading volume of 163,615 shares, compared to its average volume of 275,257. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -37.14 and a beta of 1.20. The business’s fifty day moving average price is $59.96 and its 200 day moving average price is $58.66. Morphic Holding, Inc. has a twelve month low of $24.52 and a twelve month high of $93.00.
Morphic (NASDAQ:MORF) last posted its quarterly earnings data on Wednesday, August 4th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.22). The business had revenue of $3.85 million during the quarter, compared to analyst estimates of $5.80 million. Morphic had a negative return on equity of 24.79% and a negative net margin of 158.61%. Morphic’s quarterly revenue was down 50.0% compared to the same quarter last year. As a group, equities research analysts forecast that Morphic Holding, Inc. will post -3.01 earnings per share for the current year.
Separately, Zacks Investment Research lowered Morphic from a “hold” rating to a “sell” rating in a research note on Friday, August 6th.
Morphic Company Profile
Morphic Holding, Inc operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.